We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    IMO-2125

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

This study is currently recruiting participants.
Verified November 2017 by Idera Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
First Posted: February 14, 2017
Last Update Posted: November 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Idera Pharmaceuticals, Inc.
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Condition Intervention Phase
Refractory Solid Tumors Drug: IMO-2125 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Resource links provided by NLM:

Further study details as provided by Idera Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D). [ Time Frame: 51 weeks of treatment ]
  • Objective response rate [ Time Frame: Assessed every 9 weeks for duration of study participation, which is estimated to be 51 weeks ]

Estimated Enrollment: 75
Actual Study Start Date: June 9, 2017
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMO-2125 at escalating dose levels
IMO-2125 at escalating dose levels by intratumoral injection
Drug: IMO-2125
IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
  2. Patients who have a diagnosis for which a PD-(L)-1 inhibitor has been approved must have previously received treatment with one of these therapies.

    a. Melanoma Dose Expansion: Patients must have histologically confirmed metastatic melanoma (ocular melanoma not included) which has progressed on or after treatment with a PD-(L)1 inhibitor.

  3. a) Dose Evaluation Portion: Patients should have at least one lesion accessible for intratumoral injection and biopsy.

    b) Melanoma Expansion Cohort: Patients must have at least one target lesion by Response Evaluation Criteria for Solid Tumors (RECIST v1.1). with at least one lesion accessible for injection. Tumor biopsies are not required in the expansion cohort.

  4. Patients must be 18 years of age or older.
  5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
  6. Patients must meet the following laboratory criteria:

    1. Absolute neutrophil count ANC ≥1.5 x 109/L (≥1500/mm3)
    2. Platelet count ≥75 x 109/L (≥75,000/mm3)
    3. Hemoglobin ≥8.0 g/dL (≥4.96 mmol/L)
    4. Serum creatinine ≤1.5 x ULN or calculated 24-hour creatinine clearance ≥60 mL/minute
    5. Aspartate aminotransferase (AST) ≤2.5 x ULN; ALT ≤2.5 x ULN or AST/ALT <5 x ULN if liver involvement
    6. Total bilirubin ≤1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin <3 mg/dL (51.3 μmol/L)
  7. Women of childbearing potential and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 4 weeks after the last dose of study drug.
  8. Patients must be willing and able to provide signed informed consent and comply with the study protocol.

Exclusion Criteria:

  1. Patients who have received prior therapy with a TLR agonist Patients who have received experimental vaccines or immune therapies other than PD-(L)1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., Imlygic®) should be discussed with the Medical Monitor to confirm eligibility.

    Note: (prior treatment with a topical TLR agonist (e.g. imiquimod) is permitted).

  2. Patients who have received treatment with IFN-α within the previous 6 months prior to enrollment.
  3. Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.
  4. Patients with active autoimmune disease requiring disease-modifying therapy.
  5. Patients requiring concurrent systemic steroid therapy higher than physiologic dosage (>10mg/day of prednisone or equivalent).
  6. Patients with another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer (except anaplastic).
  7. Patients with active infections requiring systemic treatment.
  8. Patients who are known to be hepatitis B surface antigen positive.
  9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.
  10. Women who are pregnant or breastfeeding.
  11. Patients with known central nervous system, meningeal, or epidural disease. Patients with stable brain metastases following definitive local treatment are eligible if steroid requirement is <10 mg/day of prednisone (or equivalent).
  12. Patients with impaired cardiac function or clinically significant cardiac disease:

    1. New York Heart Association Class III or IV cardiac disease, including preexisting clinically significant ventricular arrhythmia, congestive heart failure, or cardiomyopathy
    2. Unstable angina pectoris ≤6 months prior to study participation
    3. Acute myocardial infarction ≤6 months prior to study participation
    4. Other clinically significant heart disease (i.e., Grade ≥3 hypertension, history of labile hypertension, or poor compliance with an anti-hypertensive regimen) Must have recovered (to baseline or Grade ≤1) from toxicity associated with prior treatment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03052205

Contact: Idera Study Monitor 877-888-6550 ext 2 patientinfo@iderapharma.com

United States, Arizona
Scottsdale Healthcare Hospitals DBA Honor Health Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Joyce Schaffer, RN    480-323-1339    clinicaltrials@honorhealth.com   
The University of Arizona Cancer Center Recruiting
Tucson, Arizona, United States, 85724
Contact: Hani Babiker, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: AskRPCI    800-275-7724      
United States, Pennsylvania
St. Luke's Hospital Recruiting
Easton, Pennsylvania, United States, 18045
Contact: Jillian Timer, RN, BSN    484-503-4156    Jillian.Timer@SLUHN.org   
UPMC Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Kelsey Mitch       adamikka2@upmc.edu   
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Abha Adat       AAdat@mdanderson.org   
Sponsors and Collaborators
Idera Pharmaceuticals, Inc.
Study Director: Idera Medical Director Idera Pharmaceuticals, Inc.
  More Information

Responsible Party: Idera Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03052205     History of Changes
Other Study ID Numbers: 2125-RST-101
First Submitted: February 6, 2017
First Posted: February 14, 2017
Last Update Posted: November 16, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No